Home » Stocks » Adverum Biotechnologies

Adverum Biotechnologies, Inc. (ADVM)

Stock Price: $14.90 USD -0.69 (-4.43%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $15.53 +0.63 (4.23%) Aug 12, 6:02 PM

Stock Price Chart

Key Info

Market Cap 1.20B
Revenue (ttm) 250,000
Net Income (ttm) -87.15M
Shares Out 80.30M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $14.90
Previous Close $15.59
Change ($) -0.69
Change (%) -4.43%
Day's Open 14.93
Day's Range 13.36 - 15.97
Day's Volume 2,173,440
52-Week Range 4.96 - 26.98

More Stats

Market Cap 1.20B
Enterprise Value 942.52M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 80.30M
Float 51.65M
EPS (basic) -1.22
EPS (diluted) -1.24
FCF / Share -0.96
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.93M
Short Ratio 12.28
Short % of Float 16.24%
Beta 2.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4,785.62
PB Ratio 4.45
Revenue 250,000
Operating Income -90.30M
Net Income -87.15M
Free Cash Flow -76.78M
Net Cash 253.88M
Net Cash / Share 3.16
Gross Margin -16,067.60%
Operating Margin -36,120.80%
Profit Margin -34,859.60%
FCF Margin -30,712.00%
ROA -20.86%
ROE -37.87%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(77.85% upside)
Current: $14.90
Target: 26.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-84.49%-12.82%27.08%-37.26%305.42%19.17%1500%-
Gross Profit0.251.611.851.462.320.570.480.03
Operating Income-68.55-78.08-58.85-115-47.82-24.40-3.45-1.82
Net Income-64.49-72.63-56.15-114-47.45-25.40-5.28-1.81
Shares Outstanding64.1061.3843.6636.2525.4811.653.673.64
Earnings Per Share-1.01-1.18-1.29-3.14-1.86-2.46-1.44-0.50
Operating Cash Flow-49.17-53.96-45.42-38.37-35.34-5.65-2.18-1.27
Capital Expenditures-19.25-0.81-1.02-2.41-2.99-0.94-0.09-
Free Cash Flow-68.42-54.77-46.44-40.78-38.33-6.59-2.27-1.27
Cash & Equivalents1672061902222591590.560.36
Total Debt28.21------0.49
Net Cash / Debt1392061902222591590.56-0.13
Book Value175201184216253149-8.21-3.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adverum Biotechnologies, Inc.
Country United States
Employees 114
CEO Laurent Fischer

Stock Information

Ticker Symbol ADVM
Stock Exchange NASDAQ
Unique Identifier NASDAQ: ADVM
IPO Date July 31, 2014


Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.